Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BIS Research | PRODUCT CODE: 1413716

Cover Image

PUBLISHER: BIS Research | PRODUCT CODE: 1413716

Europe Gene Editing Technologies Market: Analysis and Forecast, 2023-2032

PUBLISHED:
PAGES: 93 Pages
DELIVERY TIME: 1-5 business days
SELECT AN OPTION
PDF and Excel (1-3 User License)
USD 2950
PDF and Excel (Global License)
USD 4450

Add to Cart

“The Europe Gene Editing Technologies Market Expected to Reach $3.26 Billion by 2032.”

Introduction to Europe Gene Editing Technologies Market

The Europe gene editing technologies market was valued at $0.37 billion in 2023 and is anticipated to reach $3.26 billion by 2032, witnessing a CAGR of 27.24% during the forecast period 2023-2032. The gene editing technologies market is anticipated to experience growth primarily due to the rising demand for personalized medicine. Furthermore, the introduction of novel technologies has further propelled the expansion of this market.

KEY MARKET STATISTICS
Forecast Period2023 - 2032
2023 Evaluation$0.37 Billion
2032 Forecast$3.26 Billion
CAGR27.24%

Market Introduction

The European gene editing technologies market is experiencing notable growth driven by the increasing demand for personalized medicine and the introduction of advanced technologies. Gene editing techniques are gaining prominence for their potential in tailoring medical treatments to individual patients, offering more effective therapies. Additionally, the emergence of novel gene editing technologies is enhancing precision and efficiency, making them increasingly valuable for research and clinical applications in Europe. The region's robust commitment to scientific research, biotechnology, and supportive regulatory frameworks creates a conducive environment for gene editing technology adoption. Ethical and responsible gene editing practices further ensure sustainable growth in this market. As gene editing continues to transform healthcare and life sciences, the European gene editing technologies market presents promising opportunities for scientific progress and therapeutic innovation.

Market Segmentation:

Segmentation 1: by Technology

  • CRISPR Gene Editing Technology
  • Non-CRISPR Gene Editing Technology

Segmentation 2: by Application

  • Agriculture
  • Biomedical

Segmentation 3: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Switzerland
  • Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The gene editing technologies market (by technology) has been segmented into CRISPR gene editing technology and non-CRISPR gene editing technology. Moreover, the study provides the reader with a detailed understanding of the different applications of gene editing technologies in agricultural and biomedical.

Growth/Marketing Strategy: Gene editing technologies are being used for agricultural, biomedical, and other applications. Various companies are providing gene editing products and services, which is also the key strategy for market players to excel in the current gene editing technologies market.

Competitive Strategy: Key players in the Europe gene editing technologies market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe gene editing technologies market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Companies Profiled:

  • BRAIN Biotech AG
  • Cellectis S.A.
  • CRISPR Therapeutics AG
  • DNA Script
  • Magento, Inc.
  • Merck KGaA
Product Code: BHL1805SS

Table of Contents

Executive Summary

1. Product Definition

  • 1.1. Inclusion and Exclusion Criteria

2. Market Scope

  • 2.1. Key Questions Answered in the Report

3. Research Methodology

4. Market Overview

  • 4.1. Market Overview
  • 4.2. Market Footprint and Potential Growth Scenario
    • 4.2.1. Realistic Growth Scenario
    • 4.2.2. Optimistic Growth Scenario
    • 4.2.3. Pessimistic Growth Scenario
  • 4.3. Evolution of Gene Editing Technologies
  • 4.4. Clinical Trials

5. Industry Outlook

  • 5.1. Regulatory Landscape
    • 5.1.1. Marketing Authorization
    • 5.1.2. USFDA Guidelines for BLA Submission
    • 5.1.3. Post-Authorization Regulations
  • 5.2. Legal Requirements and Frameworks in Europe
    • 5.2.1. EMA Biologics License Application Process
    • 5.2.2. Centralized Procedure
    • 5.2.3. Decentralized Procedure
    • 5.2.4. Mutual-Recognition Procedure
    • 5.2.5. National Procedure
  • 5.3. Expedited Regulatory Designations Around the World
  • 5.4. Product Benchmarking
    • 5.4.1. Product Benchmarking (by Technology)
    • 5.4.2. Comparative Analysis
  • 5.5. Technology Adoption Matrix
  • 5.6. Industry Trends
    • 5.6.1. Leveraging Collaboration as a Major Key Strategies to Create Opportunities for Gene Editing Technologies
    • 5.6.2. Growing Focus on Gene Therapies
  • 5.7. Patent Analysis
    • 5.7.1. Patent Analysis (by Year)
    • 5.7.2. Patent Analysis (by Technology)
    • 5.7.3. Patent Analysis (by Region)
    • 5.7.4. Patent Analysis (by Country)

6. Europe

  • 6.1. Overview
  • 6.2. Europe
    • 6.2.1. Europe Gene Editing Technologies Market (by Application)
    • 6.2.2. Europe Gene Editing Technologies Market (by Technology)
    • 6.2.3. Europe Gene Editing Technologies Market (by Country)
      • 6.2.3.1. Germany
        • 6.2.3.1.1. Germany Gene Editing Technologies Market (by Application)
        • 6.2.3.1.2. Germany Gene Editing Technologies Market (by Technology)
      • 6.2.3.2. U.K.
        • 6.2.3.2.1. U.K. Gene Editing Technologies Market (by Application)
        • 6.2.3.2.2. U.K. Gene Editing Technologies Market (by Technology)
      • 6.2.3.3. Switzerland
        • 6.2.3.3.1. Switzerland Gene Editing Technologies Market (by Application)
        • 6.2.3.3.2. Switzerland Gene Editing Technologies Market (by Technology)
      • 6.2.3.4. France
        • 6.2.3.4.1. France Gene Editing Technologies Market (by Application)
        • 6.2.3.4.2. France Gene Editing Technologies Market (by Technology)
      • 6.2.3.5. Spain
        • 6.2.3.5.1. Spain Gene Editing Technologies Market (by Application)
        • 6.2.3.5.2. Spain Gene Editing Technologies Market (by Technology)
      • 6.2.3.6. Italy
        • 6.2.3.6.1. Italy Gene Editing Technologies Market (by Application)
        • 6.2.3.6.2. Italy Gene Editing Technologies Market (by Technology)
      • 6.2.3.7. Rest-of-Europe
        • 6.2.3.7.1. Rest-of-Europe Gene Editing Technologies Market (by Application)
        • 6.2.3.7.2. Rest-of-Europe Gene Editing Technologies Market (by Technology)

7. Company Profiles

  • 7.1. BRAIN Biotech AG
    • 7.1.1. Company Overview
    • 7.1.2. Role of BRAIN Biotech AG in the Gene Editing Technologies Market
    • 7.1.3. Major Product: Key Specifications
    • 7.1.4. Key Competitors
    • 7.1.5. Financials
    • 7.1.6. Key Insights about the Financial Health of the Company
    • 7.1.7. Analyst Perspective
  • 7.2. Cellectis S.A.
    • 7.2.1. Company Overview
    • 7.2.2. Role of Cellectis S.A. in the Gene Editing Technologies Market
    • 7.2.3. Major Product: Key Specifications
    • 7.2.4. Key Competitors
    • 7.2.5. Financials
    • 7.2.6. Key Insights about the Financial Health of the Company
    • 7.2.7. Analyst Perspective
  • 7.3. CRISPR Therapeutics AG
    • 7.3.1. Company Overview
    • 7.3.2. Role of CRISPR Therapeutics AG in the Gene Editing Technologies Market
    • 7.3.3. Major Product: Key Specifications
    • 7.3.4. Key Competitors
    • 7.3.5. Financials
    • 7.3.6. Key Insights about the Financial Health of the Company
    • 7.3.7. Analyst Perspective
  • 7.4. DNA Script
    • 7.4.1. Company Overview
    • 7.4.2. Role of DNA Script in the Gene Editing Technologies Market
    • 7.4.3. Major Products: Key Specifications
    • 7.4.4. Key Competitors
    • 7.4.5. Analyst Perspective
  • 7.5. Magento, Inc.
    • 7.5.1. Company Overview
    • 7.5.2. Role of Magento, Inc. in the Gene Editing Technologies Market
    • 7.5.3. Major Products: Key Specifications
    • 7.5.4. Key Competitors
    • 7.5.5. Analyst Perspective
  • 7.6. Merck KGaA
    • 7.6.1. Company Overview
    • 7.6.2. Role of Merck KGaA in the Gene Editing Technologies Market
    • 7.6.3. Major Products: Key Specifications
    • 7.6.4. Key Competitors
    • 7.6.5. Financials
    • 7.6.6. Key Insights about the Financial Health of the Company
    • 7.6.7. Analyst Perspective
Product Code: BHL1805SS

List of Figures

  • Figure 1: Europe Gene Editing Technologies Market, $Billion, 2022-2032
  • Figure 2: Europe Gene Editing Technologies Market: Drivers, Restraints, and Opportunities
  • Figure 3: Gene Editing Technologies Market (by Technology), $Billion, 2022-2032
  • Figure 4: Europe Gene Editing Technologies Market (by Application), $Billion, 2022-2032
  • Figure 5: Gene Editing Technologies Market (by Region), $Billion, 2022 and 2032
  • Figure 6: Gene Editing Technologies Market, Share of Key Developments and Strategies (by Category), January 2018- March 2023
  • Figure 7: Gene Editing Technologies Market: Research Methodology
  • Figure 8: Primary Research Methodology
  • Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 10: Top-Down Approach (Segment-Wise Analysis)
  • Figure 11: Gene Editing Technologies Market: Market Overview
  • Figure 12: Gene Editing Technologies Market, Potential Forecast Scenarios, 2022-2032
  • Figure 13: Gene Editing Technologies Market Size and Growth Potential (Realistic Scenario), $Million, 2022-2032
  • Figure 14: Gene Editing Technologies Market Size and Growth Potential (Optimistic Scenario), $Million, 2022-2032
  • Figure 15: Gene Editing Technologies Market Size and Growth Potential (Pessimistic Scenario), $Million, 2022-2032
  • Figure 16: Evolution of Gene Editing Technologies, 1994-2020
  • Figure 17: Clinical Trial Authorization for Gene Editing
  • Figure 18: Steps for Obtaining Marketing Authorization
  • Figure 19: EMA Review Timeline
  • Figure 20: Comparison of Various Gene Editing Technologies
  • Figure 21: Gene Editing Technologies Market, Technology Adoption Matrix
  • Figure 22: Key Strategies Adopted by Major Players, January 2018- March 2023
  • Figure 23: Gene Editing Technologies Market, Patent Analysis (by Year), January 2018- December 2022
  • Figure 24: Gene Editing Technologies Market, Patent Analysis (by Technology), January 2018- December 2022
  • Figure 25: Gene Editing Technologies Market, Patent Analysis (by Region), January 2018- December 2022
  • Figure 26: Gene Editing Technologies Market, Patent Analysis (by Country), January 2018- December 2022
  • Figure 27: Gene Editing Technologies Market (by Region)
  • Figure 28: Europe: Market Dynamics
  • Figure 29: Europe Gene Editing Technologies Market, $Billion, 2022-2032
  • Figure 30: Europe Gene Editing Technologies Market (by Application), $Billion, 2022-2032
  • Figure 31: Europe Gene Editing Technologies Market (by Technology), $Billion, 2022-2032
  • Figure 32: Germany Gene Editing Technologies Market, $Million, 2022-2032
  • Figure 33: Germany Gene Editing Technologies Market (by Application), $Million, 2022-2032
  • Figure 34: Germany Gene Editing Technologies Market (by Technology), $Million, 2022-2032
  • Figure 35: U.K. Gene Editing Technologies Market, $Million, 2022-2032
  • Figure 36: U.K. Gene Editing Technologies Market (by Application), $Million, 2022-2032
  • Figure 37: U.K. Gene Editing Technologies Market (by Technology), $Million, 2022-2032
  • Figure 38: Switzerland Gene Editing Technologies Market, $Million, 2022-2032
  • Figure 39: Switzerland Gene Editing Technologies Market (by Application), $Million, 2022-2032
  • Figure 40: Switzerland Gene Editing Technologies Market (by Technology), $Million, 2022-2032
  • Figure 41: France Gene Editing Technologies Market, $Million, 2022-2032
  • Figure 42: France Gene Editing Technologies Market (by Application), $Million, 2022-2032
  • Figure 43: France Gene Editing Technologies Market (by Technology), $Million, 2022-2032
  • Figure 44: Spain Gene Editing Technologies Market, $Million, 2022-2032
  • Figure 45: Spain Gene Editing Technologies Market (by Application), $Million, 2022-2032
  • Figure 46: Spain Gene Editing Technologies Market (by Technology), $Million, 2022-2032
  • Figure 47: Italy Gene Editing Technologies Market, $Million, 2022-2032
  • Figure 48: Italy Gene Editing Technologies Market (by Application), $Million, 2022-2032
  • Figure 49: Italy Gene Editing Technologies Market (by Technology), $Million, 2022-2032
  • Figure 50: Rest-of-Europe Gene Editing Technologies Market, $Million, 2022-2032
  • Figure 51: Rest-of-Europe Gene Editing Technologies Market (by Application), $Million, 2022-2032
  • Figure 52: Rest-of-Europe Gene Editing Technologies Market (by Technology), $Million, 2022-2032
  • Figure 53: BRAIN Biotech AG: Product Portfolio
  • Figure 54: BRAIN Biotech AG: Overall Financials, $Million, 2020-2022
  • Figure 55: BRAIN Biotech AG: Revenue (by Segment), $Million, 2020-2022
  • Figure 56: BRAIN Biotech AG: Revenue (by Region), $Million, 2020-2022
  • Figure 57: BRAIN Biotech AG: R&D Expenditure, $Million, 2020-2022
  • Figure 58: Cellectis S.A.: Product Portfolio
  • Figure 59: Cellectis S.A.: Overall Financials, $Million, 2020-2022
  • Figure 60: Cellectis S.A.: R&D Expenditure, $Million, 2020-2022
  • Figure 61: CRISPR Therapeutics AG: Product Portfolio
  • Figure 62: CRISPR Therapeutics AG: Overall Financials, $Million, 2020-2022
  • Figure 63: CRISPR Therapeutics AG: R&D Expenditure, $Million, 2020-2022
  • Figure 64: DNA Script: Product Portfolio
  • Figure 65: Magento, Inc.: Product Portfolio
  • Figure 66: Merck KGaA: Product Portfolio
  • Figure 67: Merck KGaA: Overall Financials, $Million, 2020-2022
  • Figure 68: Merck KGaA: Revenue (by Segment), $Million, 2020-2022
  • Figure 69: Merck KGaA: Revenue (by Region), $Million, 2020-2022
  • Figure 70: Merck KGaA: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Parameters for Realistic, Optimistic, and Pessimistic Growth Scenarios
  • Table 3: Some of the Ongoing Clinical Trials Utilizing Various Gene Editing Technologies
  • Table 4: Expedited Regulatory Designations Around the World
  • Table 5: Gene Editing Technologies Market, Product Benchmarking (by Technology)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!